Introduction {#s1}
============

The formation of reactive oxygen species (ROS) is considered one of the key factors in chemical carcinogenesis. However, the actual role of oxidative stress remains unclear. Some reports suggest that ROS play an important role in the promotion of chemical carcinogenesis by stimulating the proliferation of initiated cells^[@r1],[@r2],[@r3]^, while others demonstrate that ROS might be an initiator by forming oxidized DNA lesions^[@r1],[@r4],[@r5],[@r6]^. 8-Hydroxydeoxyguanosine (8-OHdG) is the most abundant oxidized DNA lesion among the many oxidized nucleosides known and is fairly stable^[@r7]^. Repair of 8-OHdG is carried out by the base excision repair enzymes. In humans, OGG1, MUTYH, and MTH1 repair 8-OHdG and contribute to the protection of genomic DNA from oxidative stress^[@r8]^. The remaining 8-OHdG is considered to cause G:C to T:A transversions by mispairing with adenine and 8-OHdG^[@r9],[@r10]^.

Potassium bromate (KBrO~3~) induces renal cell tumor formation in F344 rats and has been classified as a genotoxic carcinogen because of positive mutagenicity in the Ames^[@r11]^, chromosome aberration^[@r12]^, and micronucleus tests^[@r13]^. Studies demonstrating induction of 8-OHdG by KBrO~3~*in vitro* and *in vivo* suggest that 8-OHdG plays a key role in KBrO~3~ mutagenesis and carcinogenesis^[@r14],[@r15],[@r16],[@r17]^. It was reported that KBrO~3~ produces bromine radicals, which oxidize guanine bases^[@r18]^. Additionally, our previous study using a two-stage rat renal carcinogenesis model clarified the *in vivo* mutagenicity and initiation following induction of an oxidized DNA lesion in the kidneys of rats administered KBrO~3~^[@r19]^ and showed that high amounts of 8-OHdG resulted in several types of mutations, including deletion mutations, in addition to G:C to T:A transversions^[@r19]^. The antimicrobial compound nitrofurantoin (NFT) is also known as a renal carcinogen in rats and is prohibited for veterinary use in Japan^[@r20]^. The reduction of the nitro group of NFT induces oxidative stress, which exerts antibacterial activity^[@r21],[@r22],[@r23]^. Moreover, the involvement of oxidative stress is suspected in NFT-induced carcinogenesis. In fact, our recent study showed increased levels of 8-OHdG and *gpt* mutant frequencies (MFs) with guanine base substitution mutations, including G:C to T:A transversions, in the kidneys of *gpt* delta rats treated with NFT^[@r24]^. Nonetheless, the relationship between the formation of 8-OHdG and several types of mutations, including deletion mutations and G:C to T:A transversions, remains unclear.

One of the redox-sensitive transcription factors, nuclear factor erythroid 2-related factor 2 (NRF2), regulates cellular responses to oxidative stress by transactivation of antioxidant response element (ARE)-bearing genes encoding antioxidant-related enzymes, such as NAD(P)H:quinone oxidoreductase 1 (NQO1), heme oxygenase 1 (HO1), and glutathione S-transferase (GST)^[@r25],[@r26]^. Because of the function of NRF2, *Nrf2*-deficient mice show higher sensitivity to various toxicants that induce oxidative stress^[@r27],[@r28],[@r29],[@r30],[@r31]^; therefore, these mice are quite suitable for investigation of the involvement of oxidative stress in chemical-induced genotoxicity and carcinogenesis.

In the present study, *Nrf2*-proficient and *Nrf2*-deficient mice were exposed to KBrO~3~ in drinking water or NFT in diet for 4 and 13 weeks and then subjected to reporter gene mutation assays^[@r32],[@r33]^ and measurement of 8-OHdG levels in the kidney DNA to clarify the relationship between the formation of 8-OHdG and several types of mutations. In addition, the study aimed to elucidate the detailed mechanism of oxidative stress involvement in KBrO~3~- or NFT-induced renal carcinogenesis.

Materials and Methods {#s2}
=====================

Chemicals
---------

Potassium bromate (MW 167, CAS No. 7758-01-2) and NFT (C~8~H~6~N~4~O~5~, MW 238.2, CAS No. 67-20-9) were purchased from Wako Pure Chemical Industries (Osaka, Japan) and Sigma-Aldrich (St. Louis, MO, USA), respectively.

Animals, diet, and housing conditions
-------------------------------------

The study protocol was approved by the Animal Care and Utilization Committee of the National Institute of Health Sciences. *Nrf2*-deficient mice with the C57BL/6J background established by Itoh *et al*.^[@r34]^ were crossed with *gpt* delta mice with the C57BL/6J background (Japan SLC, Shizuoka, Japan). *Nrf2*^−/−^*gpt* delta mice and *Nrf2*^+/+^*gpt* delta mice were then obtained from the F1 generation and genotyped by polymerase chain reaction (PCR) with DNA taken from the tail of each mouse. All mice were housed in polycarbonate cages (3 to 5 mice per cage) with hardwood chips for bedding in a conventional animal facility maintained at a controlled temperature (23 ± 2°C) and humidity (55 ± 5%), with 12 air changes per hour and a 12-h light/dark cycle. Mice were given free access to CRF-1 basal diet (Charles River Laboratories Japan, Kanagawa, Japan) and tap water.

Experimental design
-------------------

Six-week-old male mice of each genotype were divided into six groups (four to eight mice per group). KBrO~3~ was dissolved in distilled water at concentration of 1,500 ppm, and the prepared water was given to the animals *ad libitum* for 4 or 13 weeks. NFT was mixed in CRF-1 basal diet at concentration of 2,500 ppm, and the prepared diet was given to the animals *ad libitum* for 4 or 13 weeks. Mice of the control group were given distilled water and CRF-1 basal diet. Dose levels of KBrO~3~ and NFT were selected as each maximum dose that could be administrated to mice for 13 weeks based on a report of intestinal carcinogenesis in *Nrf2*^−/−^ mice^[@r27]^, a subacute toxicity study of KBrO~3~^[@r35]^, and a toxicology and carcinogenesis study of NFT conducted by the National Toxicology Program^[@r36]^. In the present study, the 4- and 13-week administration groups were set for the objective of detection of early changes and subsequent changes in 8-OHdG levels and *in vivo* mutagenicity induced by KBrO~3~ or NFT, respectively. Body weights were measured every week. Animals were killed by exsanguination under isoflurane (Mylan Inc., Tokyo, Japan) anesthesia. At necropsy, the bilateral kidneys were collected, and their weights were measured. The kidneys-to-body weight ratios (relative weights) were calculated as grams organ weight/grams body weight. A portion of the kidney tissues was frozen with liquid nitrogen and stored at −80°C for use in the *in vivo* mutation assay and 8-OHdG measurement. Another portion was homogenized in ISOGEN (Nippon Gene, Tokyo, Japan) and stored at −80°C until used for isolation of total RNA.

In vivo mutation assays
-----------------------

6-Thioguanine (6-TG) and Spi^--^ selections were performed using the methods described by Nohmi *et al*^[@r32]^. Briefly, genomic DNA was extracted from the kidneys of animals in each group using a RecoverEase DNA Isolation Kit (Agilent Technologies, Santa Clara, CA, USA), and lambda EG10 DNA (48 kb) was rescued as phages by *in vitro* packaging using Transpack Packaging Extract (Agilent Technologies). For 6-TG selection, packaged phages were incubated with *Escherichia coli* YG6020, which expresses Cre recombinase, and converted to plasmids carrying genes encoding glutamic--pyruvate transaminase and chloramphenicol acetyltransferase. Infected cells were mixed with molten soft agar and poured onto agar plates containing chloramphenicol and 6-TG. In order to determine the total number of rescued plasmids, infected cells were also poured on plates containing chloramphenicol without 6-TG. The plates were then incubated at 37°C for selection of 6-TG-resistant colonies, and the *gpt* MF was calculated by dividing the number of *gpt* mutants after clonal correction by the number of rescued phages. *Gpt* mutations were characterized by amplifying a 739-bp DNA fragment containing the 456-bp coding region of the *gpt* gene^[@r32]^ and sequencing the PCR products with an Applied Biosystems 3730*xl* DNA Analyzer (Life Technologies, Carlsbad, CA, USA). For Spi^--^ selection, packaged phages were incubated with *E. coli* XL-1 Blue MRA for survival titration and *E. coli* XL-1 Blue MRA P2 for mutant selection. Infected cells were mixed with molten lambda-trypticase agar and poured onto lambda-trypticase agar plates. The next day, plaques (Spi^--^ candidates) were punched out with sterilized glass pipettes, and the agar plugs were suspended in SM buffer. The Spi^--^ phenotype was confirmed by spotting the suspensions on three types of plates on which XL-1 Blue MRA, XL-1 Blue MRA P2, or WL95 P2 strain was spread with soft agar. Spi^--^ mutants, which manifested as clear plaques, were counted on every plate.

Measurement of 8-OHdG
---------------------

Three animals in each group were selected randomly, and kidneys of those animals were used for the measurement of 8-OHdG. Renal DNA of *Nrf2*^−/−^*gpt* delta mice and *Nrf2*^+/+^*gpt* delta mice was extracted and digested as described previously^[@r37]^. Briefly, nuclear DNA was extracted with a DNA Extractor WB Kit (Wako Pure Chemical Industries). For further prevention of artifactual oxidation in the cell lysis step, deferoxamine mesylate (Sigma-Aldrich) was added to the lysis buffer. The DNA was digested to deoxynucleotides by treatment with nuclease P1 and alkaline phosphatase, using an 8-OHdG Assay Preparation Reagent Set (Wako Pure Chemical Industries). The levels of 8-OHdG (8-OHdG/10^5^ dG) were measured by high-performance liquid chromatography with an electrochemical detection system (Coulochem II, ESA, Bedford, MA, USA) as previously reported^[@r19]^.

RNA isolation and quantitative real-time PCR for evaluation of mRNA expression
------------------------------------------------------------------------------

Total RNA was extracted using ISOGEN according to the manufacturer's instructions. cDNA of total RNA was obtained using a High-Capacity cDNA Reverse Transcription Kit (Life Technologies).

All PCR reactions were performed with an Applied Biosystems 7900HT FAST Real-Time PCR System with primers for mouse *Nqo1* (coding NAD(P)H:quinone oxidoreductase 1) obtained from TaqMan^®^ Gene Expression Assays and TaqMan^®^ Rodent GAPDH Control Reagents. The expression levels of the target gene were calculated by the relative standard curve method and were determined as ratios to *Gapdh* levels. Data are presented as fold-change values of treated samples relative to controls.

Statistical analysis
--------------------

The significance of differences in the results for body weights, kidney weights, mRNA expression levels, 8-OHdG levels, *gpt* and Spi^--^ MFs, and *gpt*- and Spi^--^-mutation spectra were analyzed by Student's *t*-test depending on the homogeneity. *P* values \< 0.05 were considered significant.

Results {#s3}
=======

Body and kidney weights
-----------------------

Body and kidney weights of *Nrf2*-proficient and *Nrf2*-deficient mice treated with KBrO~3~ or NFT for 4 or 13 weeks are summarized in [Fig. 1](#fig_001){ref-type="fig"}Fig. 1.Growth curves for *Nrf2*^+/+^ or *Nrf2*^−/−^ mice treated with KBrO~3~ or NFT for 4 weeks (A) or 13 weeks (B). For both genotypes, there were no significant differences in body weight between treated and untreated mice at either time point. and [Table 1](#tbl_001){ref-type="table"}Table 1.Final Body and Kidney Weights of Male *Nrf2^+/+^* or *Nrf2*^−/−^*gpt* Delta Mice Treated with KBrO~3~ or NFT for 4 or 13 Weeks. For both genotypes and time points, no significant change was observed in body and kidney weights of treated and respective control animals.

Quantitative real-time PCR for evaluation of Nqo1 mRNA expression
-----------------------------------------------------------------

Expression levels of *Nqo1* in the kidneys are shown in [Fig. 2](#fig_002){ref-type="fig"}Fig. 2.Changes in mRNA levels of the Nrf2-target gene *Nqo1* in the kidneys of *Nrf2*^+/+^ or *Nrf2*^−/−^ mice treated with KBrO~3~ or NFT for 4 weeks (A) or 13 weeks (B). Values are means ± SD. \*Significantly different (*P*\<0.05) from the respective control group. \*\*Significantly different (*P*\<0.01) from the respective control group. \#\#Significantly different (*P*\<0.01) from the respective *Nrf2*^+/+^ animals.. In *Nrf2*^+/+^ mice, the expression level of *Nqo1* was significantly increased by 4 or 13 weeks of exposure to KBrO~3~ (*P*\<0.01) and 13 weeks of exposure to NFT (*P*\<0.05). Four weeks of exposure to NFT resulted in a tendency toward increased expression of *Nqo1* in *Nrf2*^+/+^ mice. In *Nrf2*^−/−^ mice, increased *Nqo1* expression was not induced by KBrO~3~ or NFT treatment at either time point. The *Nqo1* expression levels of control, KBrO~3~-treated, and NFT-treated *Nrf2*^−/−^ mice were significantly lower (*P*\<0.01) than those of the corresponding *Nrf2*^+/+^ mice at both time points.

Measurement of 8-OHdG in kidney DNA
-----------------------------------

The results of 8-OHdG measurement in the kidneys are shown in [Fig. 3](#fig_003){ref-type="fig"}Fig. 3.8-OHdG levels in the kidneys of *Nrf2*^+/+^ or *Nrf2*^−/−^ mice treated with KBrO~3~ or NFT for 4 weeks (A) or 13 weeks (B). Values are means ± SD. \*\*Significantly different (*P*\<0.01) from the respective control group. ††Significantly different (*P*\<0.01) from the respective control group.. At both time points, KBrO~3~ treatment significantly increased the level of 8-OHdG in the kidneys of both genotypes, and the degrees of 8-OHdG increase were as follows: 4 weeks *Nrf2*^+/+^, × 2.8; 4 weeks *Nrf2*^−/−^, × 3.6; 13 weeks *Nrf2*^+/+^, × 2.1; 13 weeks *Nrf2*^−/−^, × 3.3 (vs. respective control). On the other hand, NFT treatment did not increase the level of 8-OHdG in the kidneys of either genotype at either time point. There was no significant difference in 8-OHdG level between the *Nrf2*-proficient and *Nrf2*-deficient mice of each treatment group.

In vivo mutation assay of kidneys
---------------------------------

The results of the *gpt* assay of the kidneys of *Nrf2*-proficient and *Nrf2*-deficient mice treated with KBrO~3~ or NFT are shown in [Tables 2](#tbl_002){ref-type="table"}Table 2.*Gpt* MFs in the Kidneys of *Nrf2*^+/+^ or *Nrf2*^−/−^*gpt* Delta Mice Treated with KBrO~3~ or NFT for 4 or 13 Weeks[, 3](#tbl_003){ref-type="table"}[, 4](#tbl_004){ref-type="table"}[, 5](#tbl_005){ref-type="table"}. At both time points, KBrO~3~-treated mice showed a significant increase or tendency toward increase in *gpt* MFs compared with those in the respective control groups ([Table 2](#tbl_002){ref-type="table"}). The degrees of increase in *gpt* MFs caused by 13 weeks of treatment with KBrO~3~ were as follows: *Nrf2*^+/+^, × 2.2; *Nrf2*^−/−^, × 4.4 (vs. respective control; [Table 2](#tbl_002){ref-type="table"}). Specific MFs of deletion mutations were increased in the spectrum analysis of *gpt* mutants in KBrO~3~-treated mice ([Table 3](#tbl_003){ref-type="table"}Table 3.Mmutation Spectra of *gpt* Mutant Colonies in the Kidneys of *Nrf2*^+/+^ Or *Nrf2^−/−^ gpt* Delta Mice Treated with KBrO~3~ or NFT for 4 Weeks [and 4](#tbl_004){ref-type="table"}Table 4.Mutation Spectra of *gpt* Mutant Colonies in the Kidneys of *Nrf2*^+/+^ or *Nrf2^−/−^ gpt* Delta Mice Treated with KBrO~3~ for 13 Weeks). The frequencies of deletion mutations of more than two base pairs were increased by 13 weeks of treatment with KBrO~3~ in both genotypes ([Table 4](#tbl_004){ref-type="table"}). Furthermore, in both genotypes, *gpt* MFs were increased by 13 weeks of treatment with NFT, despite no change at 4 weeks ([Table 2](#tbl_002){ref-type="table"}). The degrees of increase in *gpt* MFs caused by 13 weeks of treatment with NFT were as follows: *Nrf2*^+/+^, × 2.1; *Nrf2*^−/−^, × 3.3 (vs. respective control; [Table 2](#tbl_002){ref-type="table"}). In both genotypes, guanine base substitution mutations, including G:C to T:A or G:C to C:G transversion mutations, were increased by 13 weeks of treatment with NFT ([Table 5](#tbl_005){ref-type="table"}Table 5.Mutation Spectra of *gpt* Mutant Colonies in the Kidneys of *Nrf2*^+/+^ or *Nrf2^−/−^ gpt* Delta Mice Treated with NFT for 13 Weeks).

The results of the Spi^--^ assay of the kidneys of *Nrf2*-proficient and *Nrf2*-deficient mice treated with KBrO~3~ or NFT are shown in [Tables 6](#tbl_006){ref-type="table"}Table 6.Spi^--^ MFs in the Kidneys of *Nrf2*^+/+^ or *Nrf2^−/−^ gpt* Delta Mice Treated with KBrO~3~ or NFT for 4 or 13 Weeks[, 7](#tbl_007){ref-type="table"}Table 7.Mutation Spectra of Spi^--^ Plaques in the Kidneys of *Nrf2*^+/+^ or *Nrf2^−/−^ gpt* Delta Mice Treated with KBrO~3~ or NFT for 4 Weeks[, 8](#tbl_008){ref-type="table"}Table 8.Mutation Spectra of Spi^--^ Plaques in the Kidneys of *Nrf2*^+/+^ or *Nrf2^−/−^ gpt* Delta Mice Treated with KBrO~3~ or NFT for 13 Weeks. At both time points, KBrO~3~-treated mice showed a significant increase or tendency toward increase in Spi^--^ MFs compared with those in the respective control groups ([Table 6](#tbl_006){ref-type="table"}). The degrees of increase in Spi^--^ MFs caused by 13 weeks of treatment with KBrO~3~ were as follows: *Nrf2*^+/+^, × 3.0; *Nrf2*^−/−^, × 4.1 (vs. respective control; [Table 6](#tbl_006){ref-type="table"}). In the spectrum analysis of Spi^--^ mutants in KBrO~3~-treated mice, specific MFs of deletion mutations were increased ([Table 7 and 8](#tbl_007){ref-type="table"}), consistent with the spectrum analysis of *gpt* mutants. In both genotypes and at both time points, NFT treatment did not change Spi^--^ MFs ([Table 6](#tbl_006){ref-type="table"}).

Discussion {#s4}
==========

It is well known that transcriptional upregulation of various antioxidant enzymes, including NQO1 and HO1, is regulated by NRF2, which protect cells from oxidative stress^[@r25],[@r26]^. In several studies, *Nrf*2^−/−^ mice showed higher sensitivity to various toxicants that induced oxidative stress^[@r27],[@r28],[@r29],[@r30],[@r31]^. In fact, the mRNA expression level of *Nqo1* in the kidneys of vehicle-treated *Nrf2*^−/−^ mice was significantly lower than that of vehicle-treated *Nrf2*^+/+^ mice, and there was no elevation of the level in KBrO~3~- or NFT-treated *Nrf2*^−/−^ mice despite the elevation in *Nrf2*^+/+^ mice. Thus, in the present study, *Nrf2*^−/−^ mice were confirmed to be susceptible to oxidative stress. As previously reported, using this highly oxidative stress-sensitive animal gives us important knowledge about the involvement of oxidative stress in chemical-induced genotoxicity and carcinogenesis^[@r27],[@r28],[@r29],[@r30],[@r31]^.

Four or thirteen weeks of administration of 1,500 ppm KBrO~3~ in drinking water significantly increased the level of 8-OHdG in the kidneys of both genotypes. At both time points, the degree of 8-OHdG increase was higher in *Nrf2*^−/−^ mice than in *Nrf2*^+/+^ mice. Meanwhile, increases in *gpt* and Spi^--^ MFs were detected, and the tendencies of the degrees of increase in *gpt* and Spi^--^ MFs at 13 weeks of exposure were the same as those of 8-OHdG. In the spectrum analysis of *gpt* and Spi^--^ mutants in KBrO~3~-treated *Nrf2*^−/−^ mice, specific MFs of deletion mutations were increased, consistent with a previous study of rats^[@r24]^, and they were accompanied by an increase in the frequencies of deletion mutations of more than two base pairs. An *in vitro* report demonstrated that error in the repair process of 8-OHdG induced by KBrO~3~ treatment caused double-strand breaks (DSBs) in human cells and that DSBs resulted in a large deletion^[@r38]^. Considering these mechanisms, the increase in size of deletion mutations might reflect the accumulation of high amounts of 8-OHdG in the nuclei due to KBrO~3~. These results suggested that the formation of 8-OHdG induced by oxidative stress was directly involved in the increase of deletion mutations in KBrO~3~-treated animals. It was suspected that the formation of high amounts of 8-OHdG owing to the strong potential of KBrO~3~ as an oxidizing agent might exceed the repairing capacity of base excision repair enzymes.

Four or thirteen weeks of administration of 2,500 ppm NFT in diet did not increase the level of 8-OHdG in the kidneys of either genotype. In our previous study, the level of 8-OHdG was increased in the kidneys of *Nrf2*^−/−^ mice by oral administration of NFT at 70 mg/kg^[@r39]^. The lower exposure levels of NFT in the present study compared with those in our previous study might be a cause of the static level of 8-OHdG. On the other hand, 13 weeks administration of 2,500 ppm NFT in diet significantly increased *gpt* MFs with guanine base substitution mutations in the kidneys of both genotypes. The degree of increase in *gpt* MFs was higher in *Nrf2*^−/−^ mice than in *Nrf2*^+/+^ mice. These results implied that the vulnerability to oxidative stress caused by the deficiency of *Nrf2* leads to more mutations in NFT-treated mice. Thus, in the genotoxic mechanism of NFT, the formation of 8-OHdG induced by oxidative stress might not be involved in the increase of guanine base substitution mutations. Considering our previous studies, which suggested the involvement of oxidative stress in the chemical structure-related genotoxic mechanism of NFT in rodents^[@r24],[@r38]^, factors other than 8-OHdG might be crucial to the genotoxicity of NFT, though the present study did not identify them.

In recent years, the level of 8-OHdG has been frequently used as a marker of oxidative stress in human diseases^[@r40],[@r41]^. In addition, some reports demonstrated the involvement of oxidative stress in chemical-induced genotoxicity and carcinogenesis using the increase in 8-OHdG level as a parameter of oxidative stress in experimental animals^[@r27],[@r28],[@r29],[@r30],[@r31]^. However, the relationship between the formation of 8-OHdG and subsequent mutations, including deletion mutations and G:C to T:A transversions, had not been clarified. The revelation of the relationship between 8-OHdG and several types of mutations induced by KBrO~3~ or NFT provides new insight into oxidative stress-related *in vivo* mutagenicity.

The present study demonstrated that the formation of 8-OHdG, which resulted from the oxidizing potential of KBrO~3~, was directly involved in the increase of deletion mutations; however, oxidative stress-related factors other than 8-OHdG might play a critical role in NFT-induced guanine base substitution mutations. This was the first study to investigate the relationship between 8-OHdG and several types of mutations caused by oxidative stress-inducing chemicals. Accumulation of detailed examinations like this, such as further research on 8-OHdG with respect to individual chemical substances, will lead to accurate risk assessment of oxidative stress in carcinogenicity.
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